Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity

v3.22.1
Stockholders’ Equity
 3 Months Ended
Mar. 31, 2022
Stockholders' Equity Note [Abstract]  
Stockholders’ Equity

Note 7. Stockholders’ Equity

 

Authorized Shares

 

The Company has 45,000,000 Common shares and 900,000 Series A convertible preferred shares authorized with a par value of $0.001 per share.

 

Common Stock

 

Issuance of Shares for Vested Restricted Stock Units

 

Between January 20, 2022 and March 1, 2022, the Company issued a total of 18,666 shares of common stock to holders of fully vested restricted stock units.

 

Issuance of Shares Pursuant to Settlement of Accounts Payable

 

On March 31, 2022, the Company issued 12,196 shares of common stock in full settlement of $10,000 of accounts payable. The shares had a fair value of $0.82 per share.

 

Issuance of Shares Pursuant to Legal Settlement

 

Between January 18, 2022 and March 18, 2022, the Company issued an aggregate 71,758 shares of common stock in settlement of $75,000 pursuant to a legal settlement.

 

Equity Financing

 

During May 2020, the Company received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share. As of March 31, 2022, $415,000 worth of the shares and warrants have been issued. The remaining $125,000 received by the Company is included in equity financing within current liabilities on the consolidated balance sheet.

 

Stock Incentive Plan

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the three months ended March 31, 2022 were:

 

    Warrant Grants     Stock Option Grants     Restricted Stock Units  
   

Number of

shares
subject to warrants

     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
options		     Weighted-
average
exercise
price per
share		     Number of
shares
subject to
restricted
stock units		  
Balance at December 31, 2021     1,043,525     $ 2.57       118,388     $ 3.25       2,160,757  
Granted    
-
      
-
      
-
      
-
       443,954  
Exercised    
-
      
-
      
-
      
-
       (102,620 )
Cancelled/Expired    
-
      
-
      
-
      
-
      
-
  
Balance at March 31, 2022     1,043,525     $ 2.57       118,388     $ 3.25       2,502,091  
Exercisable at March 31, 2022     1,043,525     $ 2.57       118,388     $ 3.25       1,802,299  

The Company has classified the warrant as having Level 2 inputs, and has used the Black-Scholes option-pricing model to value the warrants.

 

The Company’s outstanding warrants and options at March 31, 2022 are as follows:

 

Warrants Outstanding   Warrants Exercisable
Exercise Price Range   Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		    

Weighted

Average
Exercise Price

     Number Exercisable   Weighted Average Exercise Price     Intrinsic Value  
$1.79 - $20.90     1,043,525       2.74     $ 2.57     1,043,525   $ 2.57      
-
  

Options Outstanding   Options Exercisable
Exercise Price Range   Number
Outstanding		     Weighted Average
Remaining
Contractual Life
(in years)		     Weighted Average
Exercise Price		     Number
Exercisable		   Weighted Average
Exercise Price		     Intrinsic Value  
$2.64 - $28.50     118,388       2.44     $ 3.25     118,388   $ 3.25      
-
  

 

As of March 31, 2022 and December 31, 2021, the total unrecognized expense for unvested stock options and restricted stock awards was approximately $1.1 million and $1.0 million, respectively, to be recognized over a twelve month to three year period from the original grant dates.

 

Stock-based compensation expense for three months ended March 31, 2022 and 2021 was as follows:

 

    For the three months ended  
    March 31,  
    2022     2021  
Stock-based compensation expense   $ 347,568     $ 500,718  

 

Stock-based compensation expense categorized by the equity components for three months ended March 31, 2022 and 2021 was as follows:

 

    For the three months ended  
    March 31,  
    2022     2021  
Common stock   $ 347,568     $ 500,718  
Total   $ 347,568     $ 500,718